6 1 8 VOLUME 16 NUMBER 6 JUNE 2015 nature immunology A20 is a deubiquitinating enzyme that inhibits activation of the tran scription factor NFκB and restricts apoptosis induced by tumornecrosis factor (TNF) [1] [2] [3] [4] . A20 is a potent antiinflammatory protein linked to multiple human autoimmune diseases and to human malignan cies 5, 6 . Polymorphisms in the human TNFAIP3 gene (which encodes A20 protein) are associated with reduced function or expression of A20 that confers susceptibility to autoimmune diseases 7, 8 . Deletion of A20 in mice leads to widespread tissue inflammation and perina tal death 2 . A20 regulates multiple signaling cascades and has distinct physiological functions in different cell types 5, 6 . In myeloid cells, A20 prevents inflammation by restricting signaling downstream of NFkB, from Tolllike receptors, the receptor Nod2 and other receptors of the innate immune system 4,9-14 . These signals lead to the produc tion of proinflammatory cytokines such as interleukin 6 (IL6) and TNF as well as costimulatory molecules that activate lymphocytes and cells of the innate immune system that lead to autoimmune and inflammatory diseases. In A20deficient B cells, exaggerated activation of NFκB triggered by the B cell antigen receptor and the costimulatory receptor CD40 leads to increased B cell survival and autoimmunity [15] [16] [17] . Hence, A20 inhibits activation of NFκB in various cell types to prevent inflammatory and autoimmune diseases. The biochemical mechanisms by which A20 restricts signals that lead to the activation of NFκB are complex and incompletely understood. Ubiquitination of signaling proteins can facilitate their recruitment to nondegradative signaling complexes, often mediated by Lys63 (K63)linked or linear polyubiquitin chains 18 . A20 is an unusual protein that utilizes two distinct motifs to remove activating K63linked polyubiquitin chains from substrates and build degradative K48linked ubiquitin chains 3, 4, 19, 20 . A20 may also disrupt interactions between the ubiquitinconjugating enzyme E2 and ubiquitin ligases E3 by destabilizing E2 enzymes 21 . A20 also has ubiquitinbinding motifs that support its interaction with the kinase RIPK1, E2 and the kinase IKKγ 19, [22] [23] [24] [25] . In addition, A20 binds members of the E3 family of ubiquitin ligases (such as TRAF2 and TRAF6), ubiquitin sensors (such as ABIN1 and ABIN2), and other proteins (such as TAX1BP1) that may act together with A20 to achieve its critical biochemical functions 26 . A20's motifs and protein interactions suggest that A20 regulates multiple signaling cascades by modifying the ubiquitination of key signaling proteins.
A20 is a deubiquitinating enzyme that inhibits activation of the tran scription factor NFκB and restricts apoptosis induced by tumornecrosis factor (TNF) [1] [2] [3] [4] . A20 is a potent antiinflammatory protein linked to multiple human autoimmune diseases and to human malignan cies 5, 6 . Polymorphisms in the human TNFAIP3 gene (which encodes A20 protein) are associated with reduced function or expression of A20 that confers susceptibility to autoimmune diseases 7, 8 . Deletion of A20 in mice leads to widespread tissue inflammation and perina tal death 2 . A20 regulates multiple signaling cascades and has distinct physiological functions in different cell types 5, 6 . In myeloid cells, A20 prevents inflammation by restricting signaling downstream of NFkB, from Tolllike receptors, the receptor Nod2 and other receptors of the innate immune system 4, [9] [10] [11] [12] [13] [14] . These signals lead to the produc tion of proinflammatory cytokines such as interleukin 6 (IL6) and TNF as well as costimulatory molecules that activate lymphocytes and cells of the innate immune system that lead to autoimmune and inflammatory diseases. In A20deficient B cells, exaggerated activation of NFκB triggered by the B cell antigen receptor and the costimulatory receptor CD40 leads to increased B cell survival and autoimmunity [15] [16] [17] . Hence, A20 inhibits activation of NFκB in various cell types to prevent inflammatory and autoimmune diseases.
The biochemical mechanisms by which A20 restricts signals that lead to the activation of NFκB are complex and incompletely understood. Ubiquitination of signaling proteins can facilitate their recruitment to nondegradative signaling complexes, often mediated by Lys63 (K63)linked or linear polyubiquitin chains 18 . A20 is an unusual protein that utilizes two distinct motifs to remove activating K63linked polyubiquitin chains from substrates and build degradative K48linked ubiquitin chains 3, 4, 19, 20 . A20 may also disrupt interactions between the ubiquitinconjugating enzyme E2 and ubiquitin ligases E3 by destabilizing E2 enzymes 21 . A20 also has ubiquitinbinding motifs that support its interaction with the kinase RIPK1, E2 and the kinase IKKγ 19, [22] [23] [24] [25] . In addition, A20 binds members of the E3 family of ubiquitin ligases (such as TRAF2 and TRAF6), ubiquitin sensors (such as ABIN1 and ABIN2), and other proteins (such as TAX1BP1) that may act together with A20 to achieve its critical biochemical functions 26 . A20's motifs and protein interactions suggest that A20 regulates multiple signaling cascades by modifying the ubiquitination of key signaling proteins.
Here we investigated the physiological function of A20 in mouse T cells. We observed decreased population expansion of A20deficient T cells due to exaggerated cell death and identified a previously unknown function for A20 in protecting T cells against necroptosis, a caspaseindependent form of programmed cell death. T cell-specific deficiency in RIPK3 restored the survival of A20deficient T cells, and global deficiency in RIPK3 partially rescued A20deficient mice (Tnfaip3 −/− mice; called 'A20 −/− ' mice here) from the perinatal death caused by A20 deficiency. Ubiquitination of RIPK3 at Lys5 (K5) supported formation of the RIPK1RIPK3 complex and necroptosis. A20 used its deubiquitinating motif to restrict the ubiquitination of RIPK3 and the formation of necroptotic RIPK1RIPK3 complexes.
RESULTS

A20 supports the survival of activated T cells
Mice with loxPflanked exon 2 of alleles encoding A20 (A20 fl/fl ) deleted by Cre recombinase expressed from the T cell-specific Cd4 promoter (A20 fl/fl CD4Cre mice) developed normally and survived for at least 6 months without gross disease (data not shown), which suggested that conditional, T cell-specific deletion of A20 did not profoundly perturb cellular immunological homeostasis. The number and frequency of CD4 + CD8 + doublepositive thymocytes and CD8 + or CD4 + singlepositive thymocytes were normal (data not shown). The total number of splenic T cells in A20 fl/fl CD4Cre mice was simi lar to that in control A20 +/fl CD4Cre mice and A20 +/+ CD4Cre mice ( Fig. 1a and data not shown), which suggested that T cell development occurred normally in the absence of A20. Analysis of T cell-activation markers revealed a greater frequency of T cells with a memory pheno type (CD44 hi CD62 lo ) in A20 fl/fl CD4Cre mice than in A20 +/fl CD4Cre mice (Fig. 1b) , which suggested a role for A20 in regulating T cell responses following exposure to antigen. Spontaneous activation of T cells in A20 fl/fl CD4Cre mice was accompanied by modestly increased number of myeloid cells (Mac1 + Gr1 + ), but not B cells (CD19 + ), compared with that in A20 +/fl CD4Cre mice (Fig. 1a) . We observed no difference between A20 +/fl CD4Cre mice and A20 +/+ CD4Cre mice in any of these parameters (data not shown), so we used A20 +/fl CD4Cre mice as controls in subsequent experiments.
To investigate the role of A20 in T cell responses, we purified naive CD4 + T cells from A20 fl/fl CD4Cre and A20 +/fl CD4Cre mice and stim ulated these cells via the T cell antigen receptor (TCR) with antibody to the invariant signaling protein CD3 (antiCD3) and antibody to the coreceptor CD28 (antiCD28). A20 fl/fl CD4Cre T cells were activated as readily as A20 +/fl CD4Cre cells were, as indicated by expression of the activation markers CD69 and CD44 and by expression of IL2 (data not shown). A20 fl/fl CD4Cre T cells stimulated via the TCR diluted the divisiontracking dye CFSE more than their A20 +/fl CD4Cre counterparts did (Fig. 1c) , which indicated that activated A20deficient CD4 + T cells cycled more than A20 +/fl CD4Cre T cells did. However, the frequency of A20 fl/fl CD4Cre T cells among total live T cells on days 2 and 3 after stimulation was markedly lower than that of A20 +/fl CD4Cre cells (Fig. 1d) , which indicated that A20 defi ciency impaired the survival of activated T cells in a cellautonomous fashion. To normalize potential differences in cytokine production and investigate the cellautonomous role of A20 in regulating T cell function, we interbred A20 fl CD4Cre mice with CD45.1 + congenic mice and stimulated equal (1:1) mixtures of sorted naive congenic A20 fl/fl CD4Cre CD4 + T cells and A20 +/fl CD4Cre CD4 + T cells in vitro. In these mixed cultures, both A20deficient and A20 sufficient T cells were exposed to the same amounts of IL2 and other T cell-derived cytokines. These experiments confirmed that A20 fl/fl CD4Cre T cell populations expanded poorly relative to A20 +/fl CD4Cre CD4 + T cell populations (data not shown). To eliminate the possibility of potential development defects contributed by A20 deficiency and to confirm that A20 directly regulated the survival of mature peripheral T cells, we interbred A20 fl/fl mice with ROSA26 ERCre mice to allow 4OHtamixifen-inducible deletion of the gene encoding A20. The resultant A20 fl/fl ROSA26ERCre mice had normal lymphoid populations (data not shown). We sorted naive CD4 + T cells from A20 fl/fl ROSA26ERCre mice and control A20 +/fl ROSA26ERCre mice, mixed the cells and stimulated them for 3 d in vitro with antiCD3 and antiCD28 in the presence of 4OHtamixifen to induce efficient deletion of A20 (Supplementary Fig. 1 ). Such 'acute' deletion of A20 resulted in greater death of A20 fl/fl ROSA26ERCre T cells than of A20 +/fl ROSA26ERCre T cells (Fig. 1e) , which suggested that A20 directly supported the survival of activated T cells.
Increased RIPK1-RIPK3 complexes in A20-deficient T cells Activated A20deficient B cells express increased amounts of the anti apoptotic factor Bclx, which renders them resistant to death mediated by the death receptor Fas (CD95) 15 . To investigate how A20 protects the survival of activated T cells, we assessed the expression of proteins of the antiapoptotic Bcl2 family in A20deficient T cells. Immunoblot analysis revealed that the expression of Bim, Bax, Bclx and Bcl2 was similar in activated A20 fl/fl CD4Cre T cells and A20 +/fl CD4Cre T cells (Fig. 2a) . We also observed that more A20 fl/fl CD4Cre T cells than A20 +/fl CD4Cre T cells died after blockade of TNF, Fas or interferonγ (IFNγ) (Fig. 2b) , which suggested that the death of A20deficient cells was not triggered by these stimuli. Notably, the pancaspase inhibitors ZVAD or QVD did not abrogate the increased suscepti bility of stimulated A20 fl/fl CD4Cre CD4 + T cells to death, compared with that of A20 fl/+ CD4Cre CD4 + T cells (Fig. 2b) ; this indicated the involvement of a caspaseindependent death pathway. Activated T cells die by necroptosis in the absence of the proapoptotic proteins FADD or caspase8 (refs. 27,28) . Necroptosis requires the kinase activity of RIPK1 and the formation of RIPK1 RIPK3 complexes [29] [30] [31] . The RIPK1kinaseactivity inhibitor necrostatin1 selectively restored the survival and population expansion of A20 fl/fl CD4Cre T cells activated via the TCR, compared with that of activated A20 +/fl CD4Cre T cells (Fig. 2b) , while an inactive form of necrostatin1 was less effective in restoring the survival of A20 fl/fl CD4Cre T cells (Supplementary Fig. 2) . Thus, the kinase activity of RIPK1 contributed to the increased death of A20deficient T cells following in vitro activation.
Immunoprecipitation of RIPK1 from CD4 + T cells activated via the TCR revealed that A20 fl/fl CD4Cre T cells contained significantly greater amounts of RIPK1associated RIPK3 than A20 +/fl CD4Cre T cells did (Fig. 2c) , which indicated that RIPK1RIPK3 complexes accumulated in A20deficient T cells and suggested that A20 protected activated T cells from necroptotic death. To further identify the role of RIPK3 in mediating the increased death of A20 fl/fl CD4Cre T cells, we interbred A20 fl/fl CD4Cre mice with Ripk3 −/− mice. Following in vitro stimulation of the TCR for 72 or 120 h in the presence of ZVAD, the number of A20 fl/fl CD4Cre Ripk3 −/− T cells was greater than that of A20 fl/fl T cells, although it was less than that of control A20 +/fl T cells (Fig. 2d) , which indicated that RIPK3 deficiency sig nificantly restored the survival of activated A20deficient T cells. The viability of caspase8deficient Jurkat I9.2 human T cells stimu lated via the TCR was reduced for cells treated with A20specific small interfering RNA (siRNA) relative to that of their counterparts treated with control siRNA, and RIPK3specific siRNA abrogated the increased death of A20deficient Jurkat I9.2 T cells observed (Fig. 2e) , which suggested that the epistatic relationship between A20 and RIPK3 was preserved in human cells. Thus, the enhanced death of activated A20deficient T cells was caspase independent, was asso ciated with increased formation of RIPK1RIPK3 complexes, and required the kinase activity of RIPK1 and the expression of RIPK3.
A20 and RIPK3 control T cell survival during in vivo activation
To determine whether A20 regulates the survival and responses of T cells in vivo, we interbred A20 fl mice with OTII mice, which trans genically express an ovalbumin (OVA)specific TCR. We adoptively VOLUME 16 NUMBER 6 JUNE 2015 nature immunology A r t i c l e s cotransferred naive A20 +/fl CD4Cre OTII (CD45.1 + CD45.2 + ) CD4 + T cells and A20 fl/fl CD4Cre OTII (CD45.1 + ) CD4 + T cells into C57BL/6 (CD45.2 + ) recipient mice, immunized the host mice with lipopolysac charide (LPS) plus OVA peptide (amino acids 323-339) at 24 h after transfer (day 0) and quantified splenic OTII T cells from each donor genotype at various time points after immunization. This experimental design allowed us to assess the response of A20deficient and A20 sufficient T cells in the same milieu of cytokines and environmental factors. Consistent with the in vitro data, A20 fl/fl CD4Cre OTII CD4 + T cell populations expanded poorly relative to the expansion of A20 +/fl CD4Cre OTII CD4 + T cell populations within the same mice, after challenge with OVA (Fig. 3a) . This result indicated that A20 supported the population expansion of activated T cells in vivo.
We next assessed the susceptibility of A20 fl/fl CD4Cre mice to experimental autoimmune encephalomyelitis (EAE), a model of T cell-mediated autoimmunity 32 . Following immunization with a myelin oligodendrocyte glycoprotein (MOG) peptide (amino acids 35-55) in complete Freund's adjuvant, A20 fl/fl CD4Cre mice developed markedly lesssevere motor neuron symptoms than those of their A20 +/fl CD4Cre counterparts (Fig. 3b) . Histological studies revealed fewer lymphoid infiltrates and greater myelin preservation in spinal cord sections from A20 fl/fl CD4Cre mice than in those from A r t i c l e s A20 +/fl CD4Cre mice ( Fig. 3c) , while ex vivo stimulation of lymph node CD4 + T cells with MOG peptide resulted in decreased proliferation of A20 fl/fl CD4Cre T cells in vitro compared with that of A20 +/fl CD4Cre T cells (Fig. 3d) . The T H 17 subset of helper T cells is important in the pathogenesis of EAE 33 . We thus quantified T H 17 cells in the lymph nodes of mice immunized with MOG peptide and found fewer T H 17 cells in A20 fl/fl CD4Cre lymph nodes than in A20 +/fl CD4Cre lymph nodes ( Fig. 3e) , which paralleled the reduction in MOGspecific A20deficient CD4 + T cells (Fig. 3d) . We next investigated whether RIPK3dependent necropto sis affected the survival of A20deficient T cells in vivo. RIPK3 is expressed in multiple tissues, and Ripk3 fl/fl mice have not yet been described. Hence, we adoptively transferred CD4 + T cells from A20 fl/fl CD4Cre Ripk3 −/− , A20 fl/fl CD4Cre Ripk3 +/+ , A20 +/fl CD4Cre Ripk3 −/− or A20 +/fl CD4Cre Ripk3 +/+ mice into lymphocytedeficient Rag1 −/− mice, which we subsequently immunized with MOG peptide. This experimental design allowed us to investigate the T cellspecific functions of A20 and RIPK3 in vivo. Rag1 −/− mice that received A20 fl/fl CD4Cre Ripk3 −/− T cells developed more severe EAE than Rag1 −/− mice that received A20 fl/fl CD4Cre Ripk3 +/+ T cells (Fig. 3f) , which suggested that abrogation of necroptosis in A20deficient T cells restored the capacity of these T cells to cause EAE. Rag1 −/− mice that received A20 +/fl CD4Cre Ripk3 −/− T cells or A20 +/fl CD4 Cre Ripk3 +/+ T cells developed more severe EAE than did mice that received A20deficient T cells (Fig. 3f) . Together these data indicated that A20 protected activated CD4 + T cells from RIPK3dependent necroptosis in vivo. A r t i c l e s A20 protects mice from RIPK3-dependent necroptosis Necroptotic death typically triggers inflammation in vivo due to the release of intracellular molecules from dying cells 34 . Tissue death and inflammation are hallmarks of A20 −/− mice 2 . To investigate whether A20 might prevent necroptosis in cells other than T cells, we derived mice bearing germline deletion of A20 fl/fl (called 'A20 KO2 mice' here) by interbreeding A20 fl/fl mice with B6.EIIACre mice (which results in deletion of loxPflanked alleles in the early mouse embryo) 15 . We bred A20 KO2 mice to C57BL/6 mice to generate A20 KO2 mice lacking the EIIACre transgene. We subsequently crossed A20 KO2 mice with Ripk3 −/− mice to generate A20 KO2/KO2 Ripk3 −/− doublemutant mice (on the C57BL/6 background). While most A20 KO2/KO2 Ripk3 +/+ mice died within 1 d of birth, A20 KO2/KO2 Ripk3 −/− mice survived 2-3 weeks (Fig. 4a) . The partial rescue of A20 KO2/KO2 mice from death through the introduction of RIPK3 deficiency suggested that increased systemic necroptosis contributed to the perinatal death of A20 KO2/KO2 mice. Because increased necroptosis of T cells was probably not the main cause of the perinatal death of A20 KO2/KO2 mice, we next assessed whether A20 directly restricted necroptosis in nonT cells. We isolated mouse embryonic fibroblasts (MEFs) from A20 KO2/KO2 and A20 +/+ mice and assessed their susceptibility to death in response to TNF, cycloheximide (CHX) and ZVAD (TNF-CHX-ZVAD), a 'cocktail' known to induce caspaseindependent necroptosis. In these conditions, as assessed by a luminescent cellviability assay, more A20 KO2/KO2 MEFs than A20 +/+ MEFs died (Fig. 4b) . Treatment of TNF-CHX-ZVAD-stimulated MEFs with necrostatin1 restored the viability of A20 KO2/KO2 MEFs to that of A20 +/+ MEFs, which suggested that the caspaseindependent death induced by the TNF-CHX-ZVAD mixture was dependent on the kinase activity of RIPK1. A20 KO2/KO2 Ripk3 −/− MEFs were more protected from TNF-CHX-ZVADinduced necroptosis than were A20 KO2/KO2 MEFs, which indicated that A20 inhibited RIPK3dependent necroptosis of these cells. Together these results indicated that A20 protected various cell types from necroptosis and suggested that uncontrolled necroptosis contributed to the perinataldeath phenotype of A20 KO2/KO2 mice. A20 inhibits pro-necroptotic RIPK1-RIPK3 complexes RIPK3dependent necroptosis involves the kinase activity of RIPK1 and the RIPK3dependent formation of RIPK1RIPK3 complexes 29, 30 . Accordingly, we assessed whether A20 restricted the formation of RIPK1RIPK3 complexes in a cellautonomous fashion. We immuno precipitated RIPK1 from A20 +/+ and A20 KO2/KO2 MEFs treated with either TNFCHX or TNF-CHX-ZVAD and analyzed RIPK3 expres sion by immunoblot. Treatment with TNF-CHX-ZVAD induced larger amounts of RIPK1associated RIPK3 in A20 KO2/KO2 MEFs than in A20 +/+ MEFs (Fig. 4c) . As phosphorylation of RIPK3 is required for the formation of necroptotic RIPK1RIPK3 complexes, we assessed the phosphorylation status of RIPK3 in A20 KO2/KO2 MEFs 29, 30 . 
A r t i c l e s
We stimulated A20 KO2/KO2 MEFs with TNF-CHX-ZVAD, immuno precipitated proteins with antiRIPK1 and then treated the immu noprecipitates with λphosphatase (or buffer alone, as a control), followed by immunoblot analyses of RIPK3. These experiments revealed that RIPK1associated RIPK3 was almost completely phosphorylated ( Fig. 4d) , which suggested that A20 inhibited the formation of pronecroptotic RIPK1RIPK3 complexes that contained phosphorylated RIPK3.
RIPK3 ubiquitination supports RIPK1-RIPK3 complexes
The laddered species at ~8kilodalton intervals detected with anti RIPK3 in the immunoprecipitates generated with antiRIPK1 ( Fig. 4c,d ) suggested that the RIPK3 proteins, rather than noncovalently associ ated coprecipitated proteins, were modified. To more precisely define the ubiquitination of RIPK3, we used an antibody directed against glycineglycine (diglycine) linked to the εamino side chain of lysine, the peptide remnant of trypsinized lysates of ubiquitinated proteins 35 . This antibody allows enrichment of ubiquitinated peptides from trypsinized lysates and can be coupled with liquid chromatographymass spectrometry to precisely identify ubiquitinated lysines in cell lysates. We used this approach to identify ubiquitinated RIPK3 peptides in necroptotic MEFs. We stimulated A20 KO2/KO2 MEFs with TNF-CHX-ZVAD, prepared lysates after 3 h, trypsinized the wholecell lysates, immunoprecipitated ubiquitinated peptides with the antibody to diglycine and performed mass spectrometry on the affinitypurified ubiquitinated peptides. Tandem mass spectra from A20 KO2/KO2 MEF lysates repeatedly revealed a precursor ion with a mass/charge (m/z) value of 1006.0525 +2 (Fig. 5a) . A database search identified this species as a peptide spanning the amino acids at positions 2-19 of RIPK3, which was acetylated at the amino ter minus and carried a diglycine remnant at Lys5 (K5) (theoretical monoisotopic m/z value of 1006.0522 +2 ). Because we observed this modification of endogenous proteins from TNF-CHX-ZVADstimulated A20 KO2/KO2 MEFs, these observations indicated that RIPK3 ubiquitination at K5 was a physiological modification. To determine if the ubiquitination of RIPK3 at K5 was dependent on A20, we performed stable isotope labeling of A20 KO2/KO2 and wildtype (A20 +/+ ) MEFs 35 . We cultured A20 KO2/KO2 MEFs for 2 weeks in medium containing amino acids labeled with a light (normal) isotope and cultured A20 +/+ MEFs for 2 weeks in medium containing amino acids labeled with a heavy isotope. We confirmed by mass spectrometry the complete replacement of endogenous amino acids by isotope labeled residues (data not shown). We then stimulated the labeled MEFs for 3 h with TNF-CHX-ZVAD, mixed lysates from A20 KO2/KO2 and A20 +/+ MEFs, trypsinized the combined lysates, immunopre cipitated ubiquitinated peptides and analyzed the products by liquid chromatography-mass spectrometry. Tandem mass spectra revealed peptide species with an m/z of ~1006 (Fig. 5b) , which indicated the pres ence of RIPK3 peptide ubiquitinated at K5 in A20 KO2/KO2 MEFs with normal ('light') isotope labeling. These spectra also revealed species at an m/z of ~1015 (Fig. 5b, left) , indicative of RIPK3 peptide modified at K5 with heavy isotope-labeled residues in A20 +/+ MEFs. Direct comparison of the relative intensity of these peaks showed that species with an m/z of ~1006 were ~15fold more abundant than species with an m/z of ~1015 (Fig. 5b, right) , which indicated that A20 KO2/KO2 MEFs contained 15fold greater amounts of K5ubiquitinated RIPK3 peptide than did A20 +/+ MEFs. As A20 KO2/KO2 MEFs expressed amounts of total RIPK3 protein similar to those expressed by A20 +/+ MEFs (Fig. 4c) , these findings indicated that the proportion as well as the total amount of RIPK3 protein that was ubiquitinated at K5 was much greater in A20deficient cells. We did not detect K5 ubiquitinated RIPK3 peptides in lysates of unstimulated A20 KO2KO2 or A20 +/+ MEFs (data not shown), which supported the notion that ubiquitination of RIPK3 at K5 was induced during necroptosis.
To determine the functional importance of the ubiquitination of RIPK3 at K5 in necroptosis, we substituted the lysine at position 5 with alanine (RIPK3(K5A)) or arginine (RIPK3(K5R)). Because the RIPK3(K5R) mutant was not stable (data not shown), we assessed the ability of RIPK3(K5A) to form RIPK1RIPK3 complexes in necroptotic cells. We virally transduced A20 KO2/KO2 Ripk3 −/− MEFs to express wildtype RIPK3 or RIPK3(K5A), sorted transduced cells expressing similar amounts of RIPK3 and analyzed the expression of RIPK1associated RIPK3 as well as the amount of cellular necropto sis following stimulation with TNF-CHX-ZVAD. MEFs expressing A r t i c l e s RIPK3(K5A) had fewer RIPK1RIPK3 complexes than did cells expressing wildtype RIPK3 (Fig. 5c) . Furthermore, cells expressing RIPK3(K5A) survived significantly better than did cells expressing wildtype RIPK3 (Fig. 5d) , which indicated that ubiquitination of RIPK3 at K5 supported the formation of RIPK1RIPK3 complexes and necroptosis.
A20 uses its deubiquitinating motif to restrict necroptosis
Polyubiquitin chains of various conformations are added to target proteins during cell signaling 18 . Because A20 restricts the ubiqui tination of RIPK1 with K63linked polyubiquitin chains 3, 4, 19 , we investigated whether A20 also inhibits the ubiquitination of RIPK3 with K63linked polyubiquitin chains. We transfected 293T human embryonic kidney cells with plasmids expressing RIPK3 and hemag glutinintagged ubiquitin in which all lysine residues except the lysine at position 63 (K63) were replaced. We immunoprecipitated proteins from cell lysates with antiRIPK3 and analyzed the immu noprecipitates by immunoblot with antihemagglutinin to reveal a ladder of K63ubiqitinated RIPK3 (Fig. 6a) . The addition of increasing amounts of plasmid encoding Flagtagged A20 to the transfection led to a progressive decrease in the amount of signal from the hemagglutinintagged ubiquitin with replacement of all lysine residues except K63 (Fig. 6a) , which indicated that A20 inhibited the K63linked ubiquitination of RIPK3 in a dosedependent fashion. In addition, following stimulation with TNF-CHX-ZVAD, we found more K63linked ubiquitination of RIPK3 in A20 KO2/KO2 MEFs than in A20 +/+ MEFs (Fig. 6b) . Thus, A20 restricted the K63linked ubiquitination of RIPK3.
To determine the mechanism by which A20 restricted the ubiquitination of RIPK3, we used MEFs from two lines of mice bearing knockin point mutations of the gene encoding A20 that abrogate the enzymatic activity of each domain of A20. A20 OTU mice bear a mutation in sequence encoding the catalytic Cys103 residue of A20 that mediates its deubiquitinating activity 19 . A20 ZF4 mice bear point mutations in sequence encoding residues Cys609 and Cys612 in the ZF4 motif that mediates the binding of A20 to ubiquiti nated RIPK1 and E2 enzymes 19, 22 . A20 ZF4/ZF4 and wildtype (A20 +/+ ) MEFs showed similar viability in response to TNF-CHX-ZVAD, whereas A20 OTU/OTU MEFs had reduced viability (Fig. 6c) , which indicated that A20 used its catalytic deubiquitinating Cys103 residue to inhibit necroptosis.
To understand how the Cys103 and ZF4 motifs of A20 regulate necroptotic signaling complexes, we analyzed the formation of RIPK1RIPK3 complexes in A20 ZF4ZF4 and A20 OTUOTU MEFs. After stimulating A20 +/+ , A20 ZF4ZF4 and A20 OTUOTU MEFs for 3 or 4 h with TNF-CHX-ZVAD, we immunoprecipitated proteins from cell lysates with antiRIPK1 and analyzed the immunoprecipitates by immuno blot with antiRIPK3. A20 OTU/OTU MEFs contained considerably more RIPK1RIPK3 complexes than did A20 +/+ or A20 ZF4/ZF4 MEFs (Fig. 6d) , while A20 ZF4/ZF4 MEFs contained slightly more RIPK1 RIPK3 complexes than did A20 +/+ or A20 +/+ MEFs (Fig. 6d) . RIPK1associated RIPK3 showed a laddered pattern indicative of ubiquitination in A20 OTU/OTU MEFs (Fig. 6d) . Following stimula tion via the TCR, A20 OTU/− T cells also had more RIPK1RIPK3 association and greater ubiquitination of RIPK3 than either A20 ZF4/− T cells or A20 +/− T cells had (Fig. 6e) , which indicated that Cys103 regulated the ubiquitination of RIPK3 and the formation of RIPK1RIPK3 complexes in T cells as well as in MEFs. A20 OTU/OTU and A20 ZF4/ZF4 T cells stimulated via the TCR and also stimulated with ZVAD exhibited phenotypes similar to those of A20 OTU/-and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16 A20 ZF4/-T cells stimulated similarly (data not shown). In addition, following 72 h of stimulation with antiCD3, antiCD28 and ZVAD, the survival of RIPK3sufficient (Ripk3 +/+ ) A20 OTU/− and A20 ZF4/− T cells was decreased compared with that of their A20 +/− counterparts (Fig. 6f) . Finally, we crossed A20 OTU and A20 ZF4 mice with Ripk3 −/− mice, isolated naive CD4 + T cells from the progeny of those crosses and assessed the response of the cells to stimulation via the TCR plus stimulation with ZVAD. Following such stimulation for 72 h, the population expansion of A20 OTU/− Ripk3 −/− CD4 + T cells was the same as that of A20 +/− Ripk3 -/-T cells, and the population expansion of A20 ZF4/− Ripk3 −/− CD4 + T cells was partially restored to that of A20 +/− T cells (Fig. 6f) , which indicated that RIPK3 deficiency restored the population expansion of A20 OTU/− CD4 + T cells and, to a lesser extent, A20 ZF4/− CD4 + T cells after such stimulation. This indicated that while the ZF4 motif of A20 was required for normal A20 activity during T cell activation, the Cys103dependent deubiquitination function of A20 was needed to inhibit the formation of RIPK1RIPK3 complexes and RIPK3dependent necroptosis.
DISCUSSION
Our study has revealed that A20 restricted necroptosis in multiple cell types. These findings suggest that A20 regulates cellular and tissue homeostasis as well as immunological homeostasis. We discovered that RIPK3 underwent a specific ubiquitination event that supported the formation of RIPK1RIPK3 complexes in cells undergoing necrop tosis, and that A20 potently inhibited this event. Our studies have broad implications for the molecular regulation of celldeath signal ing as well as the physiological mechanisms by which A20 prevents inflammatory diseases. We found that uncontrolled RIPK3dependent necroptosis in the absence of A20 inhibited T cell population expansion in vitro and in vivo. Exaggerated necroptosis in caspase8deficient T cells and T cells expressing mutant FADD has been reported to compromise anti-lymphocytic choriomeningitis virus or antitoxoplasma responses 27, 28 . Hence, our studies reinforce the concept that in certain pathological contexts, necroptosis can restrict the popula tion expansion of activated T cells. Our studies also indicated dual roles for A20 in T cells, restricting both cellular activation and cell death. Activation and survival signals appear to be integrated dif ferently in activated T cells than in activated B cells, in which A20 deficiency causes increased NFκBdependent expression of Bclx and resistance to Fasmediated death 13 . These differences reemphasize the importance of studying the cell type-specific functions of pleiotropically expressed molecules to understand their physiological roles in disease pathogenesis.
Our finding that A20 KO2/KO2 Ripk3 −/− mice lived longer than A20 KO2/KO2 Ripk3 +/+ mice suggested that A20 protects multiple cell types from necroptosis. Thus, loss of A20 from other cells (for example, stromal cells) might render mice more susceptible to necrop totic tissue damage. Our observations are consistent with published experiments showing that A20 protects L929 mouse fibrosarcoma cells from TNFinduced death 36 . RIPK3 deficiency might also abro gate inflammasome activity in A20 −/− mice 37 . Because A20 also pro tects cells from apoptotic death 2, 38 , the antinecroptotic function of A20 positions this molecule as a potent prosurvival protein. The idea that necroptosis of target organs might contribute to disease severity in inflammatory bowel disease and other conditions has been suggested 39 . Given our findings, together with observations that polymorphisms of A20 are associated with moresevere nephritic complications of patients with systemic lupus erythematosus 40 and increased disease severity in patients with psoriasis vulgaris 41 or cystic fibrosis 42 , we propose that A20 might partly prevent human disease by protecting against necroptotic death in nonlymphoid tissues.
Necroptosis is known to occur in cells lacking proapoptotic molecules such as caspase8 and FADD [43] [44] [45] [46] . This has been explained by the cleavage of RIPK1 by caspase8, which prevents RIPK1dependent A r t i c l e s formation of RIPK1RIPK3 complexes. Virusinfected cells may also undergo necroptosis when viral proteins abrogate apoptosis 30 . Hence, necroptosis has been viewed as a form of cell death that occurs predominantly in cells rendered caspase deficient. In contrast, we found that A20deficient MEFs exhibited increased sensitivity to both apoptosis and necroptosis 2 . Therefore, our findings suggest that A20 restricts necroptosis by a mechanism that is distinct from that used by caspase8 or FADD. The ubiquitination of RIPK1 inhibits its kinase activity, and the deubiquitinating enzyme CylD supports necroptosis by deubiquiti nating RIPK1 (refs. 46,47) . Like CylD, A20 inhibits RIPK1 ubiquiti nation and NFκB signaling 3, 19 . However, our findings have shown that unlike CylD, A20 inhibited necroptosis. This divergence suggests that A20 inhibits necroptosis via a mechanism other than inhibit ing the ubiquitination of RIPK1. Our finding that A20 restricted the ubiquitination of RIPK3 provides such a mechanism. K63linked ubiquitination of RIPK1 and RIPK2 occurs during NFκB signaling induced by TNF and Nod2, respectively, and A20 −/− MEFs and A20 −/− macrophages exhibit increased ubiquitination of RIPK1 and RIPK2, respectively, when stimulated through these pathways 3, 10, 19 . Hence, A20 seems to restrict the ubiquitination of RIPK1, RIPK2 and RIPK3 in distinct signaling contexts. The E3 ligases of the cIAP family are able to ubiquitinate proteins of the RIPK family in vitro, and cIAP1 and cIAP2 may be responsible for activating RIPK1 and RIPK2 by sup porting their ubiquitination with K63linked chains following activa tion of the TNF and Nod2 pathway 48, 49 . Hence, cIAP proteins might similarly activate RIPK3 through ubiquitination during necroptosis. However, cIAP proteins seem to limit necroptosis in macrophages 50 . Thus, if cIAP proteins activate RIPK3 and support the formation of RIPK1RIPK3 complexes and necroptosis, they probably also perform a separate function that restricts necroptosis (for example, cIAP proteins might ubiquitinate RIPK1). Future studies will be needed to identify the physiological E3 ligases that ubiquitinate RIPK3.
Our mass spectrometry screen identified K5 of RIPK3 as a physio logical ubiquitination site, and our stableisotopelabeling experi ments revealed that A20 −/− MEFs contained 15fold more RIPK3 peptide ubiquitinated at K5 than A20 +/+ MEFs had. Substitution of this residue abrogated the ubiquitination of RIPK3 and the forma tion of RIPK1RIPK3 complexes and necroptosis. In other signaling complexes, K63linked ubiquitination facilitates the recruitment of K63ubiquitin sensor proteins 18 . Hence, K63linked ubiquitination of RIPK3 could similarly support the recruitment of other ubiquitin sensors. These ubiquitinbinding proteins could in turn enhance the kinase activity of RIPK3, support RIPK1RIPK3 complexes, recruit downstream mediators such as MLKL 51 , and/or support higher order amyloid complexes composed of RIPK1 and RIPK3 proteins 31 . Structurally, K5 resides in an unstructured portion of RIPK3 and is thus probably accessible for ubiquitination 52 . In addition, the K5 resi due is conserved in human RIPK3, and RIPK3 deficiency abrogated the increased necroptosis of A20deficient human Jurkat I9.2 T cells. Thus, ubiquitination of RIPK3 may support necroptosis in human cells. Therefore, ubiquitination can support necroptosis, and A20 substantially inhibits this pronecroptotic ubiquitination event.
We found that the Cys103 deubiquitinating motif of A20 was required for inhibition of the ubiquitination of RIPK3 and formation of RIPK1RIPK3 complexes. The Cys103 motif cleaves unanchored K48 ubiquitin chains as well as RIPK1 or TRAF6 anchored K63 chains in cellfree experiments 3, 4, 20 . This motif has also been shown to inhibit E2E3 interactions in cells 21 . Both of these Cys103dependent activities could inhibit the K63linked polyubiquitination of RIPK3. In contrast, the ZF4 domain of A20, which binds ubiquitin and supports E3 ligase activity, appeared to be less critical than Cys103 in inhibiting the ubiquitination of RIPK3 during necroptosis. One possible explanation for this difference could be that A20, which relies on ZF4 to bind ubiquitinated RIPK1, may rely more on other ubiquitinbinding motifs, such as ZF7, to bind ubiquitinated RIPK3. Such distinct roles for the biochemical motifs of A20 might provide important insight into how A20 performs its physiological functions.
In conclusion, we have discovered that A20 restricted RIPK3 dependent necroptosis. Our studies showed that RIPK3 was physio logically ubiquitinated at K5 during necroptosis in a manner that supported the formation of RIPK1RIPK3 complexes. The regula tion of necroptosis by A20 should be integrated with the previously described roles of A20 in restricting NFκB signaling and cellular activation. As hypomorphic A20 expression and function are linked to a wide range of human inflammatory and autoimmune diseases, and as necroptosis can trigger inflammation, our studies suggest an additional pathway by which A20 prevents human disease.
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